NYSE:MEDMedifast Stock Price, Forecast & News

$103.32

+0.98 (+0.96 %)

(As of 06/1/2020 04:00 PM ET)

Add

Compare

Today's Range

$101.92

Now: $103.32▼

$106.64

50-Day Range

$64.29

MA: $81.94▼

$102.34

52-Week Range

$49.03

Now: $103.32▼

$142.97

Volume218,613 shs

Average Volume292,313 shs

Market Capitalization$1.22 billion

P/E Ratio16.43

Dividend Yield4.42%

Beta1.23

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands. The company sells its products through various channels, including the Internet, call centers, independent health advisors, franchise weight loss clinics, and direct consumer marketing. The company was founded in 1980 and is headquartered in Baltimore, Maryland.

Beat the Market (BTM) Rank^™

1.0 Analyst's Opinion

Consensus Rating
Medifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $88.00, Medifast has a potential downside of 14.8% from its current price of $103.32.
Amount of Analyst Coverage
Medifast has only been the subject of 1 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Medifast has received 349 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Medifast has received 365 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Medifast has received 51.12% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Medifast and other stocks. Vote “Outperform” if you believe MED will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MED will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Leadership
Medifast is a leading dividend payer. It pays a dividend yield of 4.42%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Medifast has only been increasing its dividend for 3 years.
Dividend Coverage
The dividend payout ratio of Medifast is 75.84 %. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, Medifast will have a dividend payout ratio of 60.27 % next year. This indicates that Medifast will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Medifast insiders have sold 3,517.16% more of their company's stock than they have bought. Specifically, they have bought $12,543.00 in company stock and sold $453,700.00 in company stock.
Percentage Held by Insiders
Only 5.50% of the stock of Medifast is held by insiders.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Medifast are expected to grow by 10.46% in the coming year, from $6.79 to $7.50 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Medifast is 16.43, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.51.
Price to Earnings Ratio vs. Sector
The P/E ratio of Medifast is 16.43, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 30.40.
Price to Book Value per Share Ratio
Medifast has a P/B Ratio of 11.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.43 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Miscellaneous food preparations & kindred products

Sub-IndustryPersonal Products

SectorConsumer Staples

Current SymbolNYSE:MED

Previous Symbol

CUSIP58470H10

CIK910329

Webwww.medifast1.com

Phone410-581-8042

Debt

Debt-to-Equity RatioN/A

Current Ratio1.97

Quick Ratio1.39

Price-To-Earnings

Trailing P/E Ratio16.43

Forward P/E Ratio15.22

P/E GrowthN/A

Sales & Book Value

Annual Sales$713.67 million

Price / Sales1.71

Cash Flow$6.72 per share

Price / Cash Flow15.38

Book Value$9.03 per share

Price / Book11.44

Profitability

EPS (Most Recent Fiscal Year)$5.96

Net Income$77.92 million

Net Margins10.41%

Return on Equity65.66%

Return on Assets36.80%

Miscellaneous

Employees420

Outstanding Shares11,780,000

Market Cap$1.22 billion

Next Earnings Date8/6/2020 (Estimated)

OptionableOptionable

Receive MED News and Ratings via Email

Sign-up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.

Medifast (NYSE:MED) Frequently Asked Questions

How has Medifast's stock been impacted by COVID-19 (Coronavirus)?

Medifast's stock was trading at $70.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MED stock has increased by 46.7% and is now trading at $103.32. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Medifast?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Medifast.

When is Medifast's next earnings date?

Medifast is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Medifast.

How were Medifast's earnings last quarter?

Medifast Inc (NYSE:MED) issued its quarterly earnings results on Tuesday, May, 5th. The specialty retailer reported $1.93 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.33 by $0.60. The specialty retailer earned $178.46 million during the quarter, compared to the consensus estimate of $161.90 million. Medifast had a net margin of 10.41% and a return on equity of 65.66%. View Medifast's earnings history.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast declared a quarterly dividend on Thursday, March 19th. Stockholders of record on Tuesday, March 31st will be paid a dividend of $1.13 per share on Wednesday, May 6th. This represents a $4.52 annualized dividend and a yield of 4.37%. The ex-dividend date of this dividend is Monday, March 30th. View Medifast's dividend history.

What price target have analysts set for MED?

3 equities research analysts have issued twelve-month price targets for Medifast's shares. Their forecasts range from $86.00 to $90.00. On average, they expect Medifast's stock price to reach $88.00 in the next twelve months. This suggests that the stock has a possible downside of 14.8%. View analysts' price targets for Medifast.

Has Medifast been receiving favorable news coverage?

News articles about MED stock have been trending very positive this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medifast earned a news sentiment score of 3.5 on InfoTrie's scale. They also assigned headlines about the specialty retailer a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutMedifast.

Who are some of Medifast's key competitors?

Some companies that are related to Medifast include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Prestige Consumer Healthcare (PBH), Nu Skin Enterprises (NUS), USANA Health Sciences (USNA), Inter Parfums (IPAR), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR). View all competitors.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Boeing (BA), Mastercard (MA), Micron Technology (MU), AbbVie (ABBV), Adobe (ADBE), Paypal (PYPL) and Baidu (BIDU).

Who are Medifast's key executives?

Medifast's management team includes the following people:

Mr. Daniel R. Chard, CEO & Director (Age 54)
Mr. Timothy G. Robinson CPA, CPA, Chief Financial Officer (Age 57)
Mr. William Baker IV, Exec. VP of Information Technology (Age 47)
Mr. Nicholas Johnson, Exec. VP of Coach Success Market Pres of OPTAVIA USA (Age 39)
Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 48)

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Who are Medifast's major shareholders?

Medifast's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.05%), Rice Hall James & Associates LLC (3.57%), Rice Hall James & Associates LLC (3.57%), State Street Corp (2.96%), Pictet Asset Management Ltd. (2.25%) and Bank of New York Mellon Corp (2.02%). Company insiders that own Medifast stock include Carl E Sassano, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Michael A Hoer, Michael C Macdonald and Scott Schlackman. View institutional ownership trends for Medifast.

Which institutional investors are selling Medifast stock?

MED stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., BlackRock Inc., Acadian Asset Management LLC, BNP Paribas Arbitrage SA, Morgan Stanley, Morgan Stanley, Parametric Portfolio Associates LLC, and Engine Capital Management LP. View insider buying and selling activity for Medifast.

Which institutional investors are buying Medifast stock?

MED stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Schroder Investment Management Group, Federated Hermes Inc., Robeco Institutional Asset Management B.V., Deutsche Bank AG, Nuveen Asset Management LLC, Bridge City Capital LLC, and State Street Corp. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, Jeffrey J Brown, and Michael A Hoer. View insider buying and selling activity for Medifast.

How do I buy shares of Medifast?

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $103.32.

How big of a company is Medifast?

Medifast has a market capitalization of $1.22 billion and generates $713.67 million in revenue each year. The specialty retailer earns $77.92 million in net income (profit) each year or $5.96 on an earnings per share basis. Medifast employs 420 workers across the globe.

What is Medifast's official website?

The official website for Medifast is www.medifast1.com.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff